FDA approves IND application for GNTbm-38 for Ph 1 trial in Advanced Solid Tumors and R/R PTCL
Dr. Chia-Nan Chen, Chairman of GNTbm, stated: “GNTbm-38 is a new generation anti-cancer immunotherapy drug independently developed by the GNTbm R&D team after years of experiences on developing new drug Kepida®.” GNTbm-38 is a brand new orally administered new chemical entity drug independently developed in Taiwan. GNTbm-38 has excellent epigenetic regulation and immune activation mechanisms, which can control the on-off switches of genes and further impact the expression of genes and proteins at a deeper level. The R&D team of GNTbm has already planned a clinical development strategy for multiple indications for GNTbm-38, prioritizing the development of relapsed or refractory peripheral T-cell lymphoma to obtain orphan drug designation; subsequently, new indications will be expanded. GNTbm-38 is a broad-spectrum, oral, anti-cancer new drug with immense development potential. It can be used in combination with drugs of different mechanisms, including unique multi-kinase inhibitors, immune checkpoint inhibitors, or anti-PD-1/VEGF bispecific antibodies, generating stronger synergistic anti-cancer effects and providing patients with better treatment benefits.
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.